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Introduction: Myeloma causes profound immunodeficiency and
recurrent, serious infections. There are approximately 5,500 new
UK cases of myeloma per annum; a quarter will have a serious
infection within 3 months of diagnosis. Newly diagnosed patients
may benefit from antibiotic prophylaxis to prevent infection and
early death but this may be associated with healthcare-associated
infections
Methods: The Tackling Early Morbidity and Mortality in Myeloma trial
(TEAMM) trial was a multicentre randomised, double-blind, placebo-
controlled trial in newly-diagnosed myeloma patients randomised to
receive Levofloxacin or placebo for 12 weeks at the start of anti-
myeloma treatment. Follow-up was 4-weekly to 16 weeks and again
at 1 year. The composite primary outcome was defined as time to
first febrile episode or death in the first 12 weeks from start of trial
treatment. Secondary outcomes included overall survival at 16 weeks
up to 12 months.
Results: 977 patients were randomised (489 levofloxacin, 488 pla-
cebo). Primary events (febrile episodes, deaths, febrile episodes with
death) in levofloxacin versus placebo arms were 19% vs 27% (87, 4, 4
vs 112, 15, 7), respectively; HR=0.66 (95% CI 0.51-0.86) p=0.002. There
was a benefit in overall survival at 12 weeks (p=0.008) but not at 12
months (p=0.94).
Conclusions: The use of 12 weeks prophylactic antibiotics signifi-
cantly reduced the number of febrile episodes or deaths within the
first 16 weeks. However, this did not predict longer-term survival.
Models to adjust for additional treatments indicated that the use of
co-trimoxazole was independently associated with improved survival.
TEAMM demonstrates the need for longer-term follow-up in cancer
trials. This has influenced the design of TEAMM2 trial.
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